Dermatol. praxi. 2019;13(1):45-48 | DOI: 10.36290/der.2019.007
Tofacitinib in treating psoriatic arthritis
- Revmatologický ústav a Revmatologická klinika, 1. lékařská fakulta Univerzity Karlovy, Praha
The treatment of psoriatic arthritis (PsA) requires a multidisciplinary approach of a wide range of specializations in order to achieve remission, or at least a low activity of all disease manifestations, both musculoskeletal and dermal ones. Over the years, more therapeutic options have been developed allowing a more effective treatment in patients with a form of PsA particularly resistant to conventional therapy. Tofacitinib is a selective Janus kinase inhibitor whose efficacy and safety has been shown in a number of clinical trials of the OPAL programme in PsA. Data obtained from clinical trials have led to the introduction of tofacitinib in the treatment of moderately to highly active PsA in which there was failure of the previous conventional or biological therapy. This review deals with tofacitinib indicated to treat PsA.
Keywords: psoriatic arthritis, tofacitinib, biological therapy, JAK
Published: March 21, 2019 Show citation
References
- Celis R, Planell N, Fernández-Sueiro JL, et al. Synovial cytokine expression in psoriatic arthritis and associations with lymphoid neogenesis and clinical features. Arthritis Res Ther 2012; 27 :R9
Go to original source... 
Go to PubMed... - Maharaj AB, Chandran V. Treatment of psoriatic arthritis with traditional DMARD's and novel therapies: approaches and recommendations. Expert Rev Clin Immunol. 2016; 18: 1-13 Go to original source...
- D,Angelo S, Tramontano G, Gilio M et al. Review of the treatment of psoriatic arthritis with biological agents: choice of drug for initial therapy and switch therapy for non-responders. Open Access Rheumatol. 2017;2: 9: 21-28. Go to original source... Go to PubMed...
- Ghoreschi K, Laurence A, O,Shea JJ. Janus kinases in immune cell signaling. Immunol Rev 2009; 228(1): 273-287. Go to original source... Go to PubMed...
- O,Shea JJ, Murray PJ. Cytokine signaling modules in inflammatory responses. Immunity 2008; 28: 477-487 Go to original source... Go to PubMed...
- https://www.ema.europa.eu/documents/product-information/xeljanz-epar-product-information_cs.pdf
- Gladman D, Rigby W, Azevedo VF, et al. Tofacitinib for psoriatic arthritis in patients with an inadequate response to TNF inhibitors. N Engl J Med. 2017; 377: 1525-1536. Go to original source... Go to PubMed...
- Mease P, Hall S, Fitzgerald O, et al. Tofacitinib or adalimumab versus placebo for psoriatic arthritis. N Engl J Med. 2017; 377: 1537-1550. Go to original source... Go to PubMed...
- Lawendy N, Krishnaswami S, Wang R, et al. Effect of CP-690,550, an orally active Janus kinase inhibitor, on renal function in healthy adult volunteers. J Clin Pharmacol 2009; 49: 423-429. Go to original source... Go to PubMed...
- Hodge JA, Kawabata TT, Krishnaswami S, et al. The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis. Clin Exp Rheumatol 2016, 34: 318-328. Go to PubMed...
- Fleischmann R, Wollenhaupt J, Takiya L, et al. Safety and maintenance of response for tofacitinib monotherapy and combination therapy in rheumatoid arthritis: an analysis of pooled data from open-label long-term extension studies. RMD Open. 2017; 3(2): e000491. Go to original source... Go to PubMed...
- van der Heijde D, Tanaka Y, Fleischmann R, et al; ORAL Scan Investigators. Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data, from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 2013; 65: 559-570. Go to original source... Go to PubMed...
- Papp KA, Menter MA, Abe M et al OPT Pivotal 1 and OPT Pivotal 2 investigators. Tofacitinib, an oral Janus kinase inhibitor, for the treatment of chronic plaque psoriasis: results from two randomized, placebo-controlled, phase III trials. Br J Dermatol. 2015 Oct; 173(4): 949-961. Go to original source... Go to PubMed...